Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Komazaki, T.
Right arrow Articles by Kishimoto, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Komazaki, T.
Right arrow Articles by Kishimoto, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 34:191-194 (2004)
© 2004 Foundation for Promotion of Cancer Research

Hypermethylation-associated Inactivation of the SOCS-1 Gene, a JAK/STAT Inhibitor, in Human Pancreatic Cancers

Toshiaki Komazaki1,3, Hisaki Nagai1, Mitsuru Emi1, Yoshie Terada1, Aya Yabe1, Enjing Jin2, Ooiti Kawanami2, Noboru Konishi4, Yukichi Moriyama3, Tetsuji Naka5 and Tadamitsu Kishimoto5,+

1 Department of Molecular Biology and 2 Department of Pathology, Institute of Gerontology, Nippon Medical School, Kawasaki, Kanagawa, 3 Center for Digestive Diseases, Nippon Medical School, Kawasaki, Kanagawa, 4 Department of Pathology, Nara Medical University, Kashihara, Nara and 5 Department of Medicine III, Osaka University Medical School, Osaka, Japan

Background: SOCS-1, a JAK-binding protein (SSI-1/SOCS-1/JAB), regulates the JAK/STAT signal transduction pathway that relays signals from various cytokines in the extracellular matrix into the cell. Inactivation of the SOCS-1 gene by methylation has been previously described in hepatocellular carcinomas and multiple myeloma. The purpose of the present work was to analyze the expression of the SOCS-1 gene and identify inactivation of this gene by methylation in pancreatic cancers.

Methods: 20 samples were analyzed. We identified the expression of SOCS-1 gene using RT-PCR and the mechanism of inactivation in this gene by methylation assay.

Results: We documented marked suppression of SOCS-1 mRNA and reduction of SOCS-1 protein in 7 of 14 primary pancreatic cancers examined; moreover, CpG-rich regions upstream of the SOCS-1 gene were hypermethylated in 8 of the 14 tumors.

Conclusions: The results suggested that this gene is silenced in a substantial portion of pancreatic cancers through mechanisms that cause methylation in the promoter region.

+ For reprints and all correspondence: Mitsuru Emi, Department of Molecular Biology, Institute of Gerontology, Nippon Medical School, 1–396, Kosugi-cho, Nakahara-ku, Kawasaki 211–8533, Japan. E-mail: memi{at}nms.ac.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
K. L. Wu, H. Miao, and S. Khan
JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism
Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1836 - F1846.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
W. Komyod, M. Bohm, D. Metze, P. C. Heinrich, and I. Behrmann
Constitutive Suppressor of Cytokine Signaling 3 Expression Confers a Growth Advantage to a Human Melanoma Cell Line
Mol. Cancer Res., March 1, 2007; 5(3): 271 - 281.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.